Phosphorylated Derivatives of Transportan 10 for Cellular Delivery of Oligonucleotides (2011)
Sequence: Stearyl-AGYLLGKT(PO3)NLKALAALAKKIL-NH2
splice-correcting oligonucleotide (SCO)
| Experiment Id | EXP001605 |
|---|---|
| Paper | Phosphorylated Derivatives of Transportan 10 for Cellular Delivery of Oligonucleotides |
| Peptide | NickFect2 (NF2) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | High |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 1.4 |
| Rna Concentration | 0.2 |
| Mixing Ratio | 7:1 (peptide:ON molar ratio); also tested 1:1–15:1 |
| Formulation Format | non-covalent peptide:ON nanocomplexes (co-incubation) |
| Formulation Components | stearylated peptide + SCO (phosphorothioate 2'-O-methyl ON) |
| Size Nm | 975.80 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa pLuc 705 |
| Animal Model | |
| Administration Route | |
| Output Type | splice correction (luciferase activity) |
| Output Value | Up to ~400-fold increase vs untreated (serum-free, MR 7:1) |
| Output Units | |
| Output Notes | Similar in serum-free to NF1; lower than NF1 in serum-containing medium; ~4× higher than Lipofectamine 2000 in vitro |
| Toxicity Notes | Slightly more cytotoxic than NF1 under same conditions but less toxic than Lipofectamine 2000 |
| Curation Notes |